Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 24, 2009

Sepracor Reports $45M Profit, Raises Expectations

Marlborough-based drug maker Sepracor Inc. reported a second quarter profit plunge from $380 million a year ago to $44.9 million as of the end of June this year.

The company, which makes the sleep drug Lunesta, said the profit decline was the result of a gain from an income tax benefit related to deferred tax assets during the second quarter of 2008. Excluding the tax benefit and a charge related to research and development, the company's profit for the second quarter of 2008 was $7.5 million.

Revenue for the quarter increased 11 percent to $362.2 million, $151.3 million of which was brought in by sales of Lunesta. For the first half of the year, revenue increased 7 percent to $656.4 million. Profit for the half decreased from $388 million in 2008 to $80 million.

The company said it expects revenue for the year between $1.22 billion and $1.27 billion. The company's previous earnings guidance was for between $1.15 billion and $1.25 billion.

Sign up for Enews

WBJ Web Partners

0 Comments

Register for free to read more articles.

Register Now

Already have an online account? Login

To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy

Allow Cookies